Data / Drug companies / B. Braun Medical Inc.
B. Braun Medical Inc.: 97 products in the FDA NDC directory, labeler code 0264
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
B. Braun Medical Inc. (labeler code 0264) lists 97 products in the FDA National Drug Code Directory, covering 37 finished drugs by generic name. By type: 97 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 1, 2026.
The request: Watch B. Braun Medical Inc. (FDA labeler code 0264): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0264
- Products in commercial distribution
- 97
- Packages
- 135
- Finished drugs by generic name
- 37
- Prescription products
- 97
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 2
- Flagged as original packager
- 76 of 76 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- September 10, 1970
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 79 | 81.4% |
| Generic drugs (ANDA) | 18 | 18.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 97 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 49 | 50.5% |
| Injection | 26 | 26.8% |
| Solution | 13 | 13.4% |
| Irrigant | 8 | 8.2% |
| Injection, solution, concentrate | 1 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lactated Ringers | 0264-7500 | Injection, solution | New drug applications (NDA) | October 1, 2026 |
| Sugammadex | 0264-8200 | Injection | Generic drugs (ANDA) | July 28, 2026 |
| Rocuronium Bromide | 0264-5711 | Injection | New drug applications (NDA) | May 21, 2026 |
| Midazolam in 0.8% sodium chloride | 0264-8005 | Injection, solution | Generic drugs (ANDA) | October 15, 2025 |
| Midazolam in 0.8% sodium chloride | 0264-8002 | Injection, solution | Generic drugs (ANDA) | October 15, 2025 |
| Piperacillin and Tazobactam and Sodium Chloride | 0264-3450 | Injection, solution | New drug applications (NDA) | September 30, 2025 |
| Piperacillin and Tazobactam and Sodium Chloride | 0264-3448 | Injection, solution | New drug applications (NDA) | September 30, 2025 |
| Piperacillin and Tazobactam and Sodium Chloride | 0264-3446 | Injection, solution | New drug applications (NDA) | September 30, 2025 |
| Tromethamine | 0264-8031 | Injection, solution | Generic drugs (ANDA) | August 27, 2025 |
| Heparin Sodium in Sodium Chloride | 0264-3462 | Injection | New drug applications (NDA) | July 18, 2025 |
| Heparin Sodium in Sodium Chloride | 0264-3301 | Injection | New drug applications (NDA) | July 18, 2025 |
| Cefazolin Sodium | 0264-3107 | Solution | New drug applications (NDA) | March 10, 2025 |
| Levetiracetam | 0264-5009 | Injection | Generic drugs (ANDA) | May 13, 2024 |
| Levetiracetam | 0264-1509 | Injection | Generic drugs (ANDA) | May 13, 2024 |
| Levetiracetam | 0264-1009 | Injection | Generic drugs (ANDA) | May 13, 2024 |
| Lactated Ringers | 0264-7750 | Injection, solution | New drug applications (NDA) | April 26, 2024 |
| Calcium Gluconate | 0264-5600 | Injection, solution | Generic drugs (ANDA) | November 2, 2023 |
| Acetaminophen | 0264-4050 | Injection | New drug applications (NDA) | October 10, 2023 |
| Potassium chloride | 0264-1944 | Injection, solution, concentrate | Generic drugs (ANDA) | May 2, 2022 |
| Balanced Salt | 0264-1945 | Solution | Generic drugs (ANDA) | January 28, 2022 |
| LIDOCAINE HCl and EPINEPHRINE | 0264-9378 | Injection | Generic drugs (ANDA) | September 8, 2021 |
| Magnesium Sulfate in Water | 0264-4206 | Injection, solution | Generic drugs (ANDA) | April 26, 2021 |
| Magnesium Sulfate in Water | 0264-4205 | Injection, solution | Generic drugs (ANDA) | April 26, 2021 |
| Magnesium Sulfate in Water | 0264-4204 | Injection, solution | Generic drugs (ANDA) | April 26, 2021 |
| Acetaminophen | 0264-4100 | Injection | New drug applications (NDA) | February 18, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.